Skip to content
Biotechnology, Medical Health Aged Care

Island Pharmaceuticals doses first cohort in ISLA-101 Single Ascending Dose study

Island Pharmaceuticals < 1 mins read
  • The Single Ascending Dose study is a dose escalation study, in which three cohorts of healthy subjects will receive escalating doses of ISLA-101
  • Study will ensure that administered doses can safely achieve blood concentrations of ISLA-101 that are predicted to be effective against the dengue virus
  • Data readout from the study is expected in early 2024

 

MELBOURNE Australia, 24 November 2023: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; “Island”; “the Company”) is pleased to announce that it has dosed the first cohort in its Single Ascending Dose (SAD) study for ISLA-101, a well-known drug candidate being repurposed for the prevention and treatment of dengue and other mosquito (or vector) borne diseases.

 

The Single Ascending Dose study is being run at Scientia Clinical Research’s clinical trial facilities in Sydney (NSW), Australia, by Contract Research Organisation, Beyond Drug Development (ASX: 25 September 2023).

 

Study results are expected in early 2024. The insights gained from this study will pave the way for optimising protocols for Island’s planned Phase 2a PEACH clinical trial.

 

CEO of Island Pharmaceuticals, Dr David Foster said, “We are delighted to see the start of this study with the dosing of our first subject. This news represents a critical step in our journey towards our PEACH clinical trial, and progressing ISLA-101toward approval as a much-needed treatment for dengue fever and other mosquito borne diseases.”


About us:

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectiousdiseases. Our lead asset is ISLA-101, a drug with a well- established safety profile, being repurposed for the prevention andtreatment of denguefever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher"at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority ReviewVoucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company’s website.

Visit www.islandpharmaceuticals.com for more on Island.


Contact details:

Jane Lowe

IR  Department Mobile: +61 411 117 774

jane.lowe@irdepartment.com.au

Media

More from this category

  • Disability, Medical Health Aged Care
  • 26/02/2024
  • 23:25
Mr River Night, National Disability Sector Advocate

Disability Sector Outrage as Both Major Parties Snub Australia’s Biggest Disability and NDIS Related Event in History Coming Up this Week in Queensland

Available for Comment Radio – Live, Pre-recorded and Talk-back TV Print Mr River Night Leading National Disability Sector Advocate Co-founder at Developing Australian Communities…

  • Contains:
  • Medical Health Aged Care
  • 26/02/2024
  • 10:55
Arthritis Australia & Monash University

Millennials Face a Painful & Stiff Future – New Report Forecasts Generations Hit Hardest with Arthritis

MEDIA INTERVIEW/FILMING OPPORTUNITY Tuesday 27 February 2024 8.00 – 9.00am New forecasts by researchers at Monash University’s School of Public Health & Preventive Medicine, to be released by Arthritis Australia, reveal millennials are on the front line of a painful and debilitating future health crisis in 2040. It predicts, 1 in 6 millennials will be suffering from arthritis by 2040 as they step into what would be their most productive and fulfilling decades. What aging means for this generation will be redefined as they grapple with the challenges of today’s world and become the generation impacted the most by arthritis…

  • Medical Health Aged Care
  • 26/02/2024
  • 09:00
Dementia Australia

Dementia Australia supports Longreach and Winton

Are you concerned about your memory or worried that someone you know may have dementia? Dementia Australia is offering support in Longreach and Winton between 11 March to 15 March. It is estimated there are almost 84,000 people living with dementia in Queensland. Without a medical breakthrough this number is expected to increase to more than 168,000 people living with dementia by 2054. These Dementia Australia sessions are an opportunity for people living with dementia, their carers, family, and friends to attend free education to better understand dementia and to discuss the support and services Dementia Australia can provide. Please…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.